This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/AHFS/
n20http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/mixture/
n23http://www.drugs.com/ppa/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/bindingdb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/pubchem-compound/
n22http://www.rxlist.com/
n9http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/kegg-drug/
n14http://www.pdrhealth.com/drugs/rx/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/patent/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06700/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n29http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06700
rdf:type
n3:Drug
n3:description
Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.
n3:dosage
n10:271B4F41-363D-11E5-9242-09173F13E4C5 n10:271B4F42-363D-11E5-9242-09173F13E4C5 n10:271B4F43-363D-11E5-9242-09173F13E4C5 n10:271B4F40-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of Infant Dose Through Milk in a Lactating Woman Taking Amisulpride and Desvenlafaxine for Treatment-Resistant Depression. Ther Drug Monit. 2010 Oct 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20926994 # Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19086875 # Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20797382 # Liebowitz MR, Tourian KA: Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder:A Systematic Review of Clinical Trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20944767 # Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17673606 # Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov;24(6):296-305. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19779354 # Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19629022 # Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs. 2009 Jan;10(1):75-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19127490 # Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19919295 # Wyeth Laboratories Inc. Pristiq® (desvenlafaxine succinate) extended-release tablets prescribing information. Philadelphia, PA; 2010 Sept. # FDA label # Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22098230 # http://www.pharmgkb.org/pathway/PA166014758 # Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19142106
n3:group
approved
n3:halfLife
The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.
n3:indication
Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
owl:sameAs
n9:DB06700 n21:DB06700
dcterms:title
Desvenlafaxine
adms:identifier
n12:D02570 n15:0008-1211-14 n16:DB06700 n17:50010875 n18:111300 n19:PA165958374 n20:Desvenlafaxine n24:125017 n25:99443254
n3:mechanismOfAction
Desvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.
n3:patent
n7:6673838 n7:2436668
n3:routeOfElimination
Excreted in the urine. Approximately 45% of the total oral dose is excreted unchanged in urine. Approximately 19% of the total oral dose is excreted as the glucuronide metabolite and < 5% is excreted as the oxidative metabolite, N,O-didesmethylvenlafaxine. Excreted in human milk.
n3:synonym
Desvenlafaxine ODV O-desmethylvenlafaxine Pristiq
n3:toxicity
The safety and tolerability of desvenlafaxine is similar to other SNRIs. Common side effects upon initiation or dose increase include increased blood pressure and heart rate, agitation, tremor, sweating, nausea, headache, and sleep disturbances. May cause sexual dysfunction and weight loss in some patients. May cause increases in fasting serum total cholesterol, LDL cholesterol, and triglycerides. Withdrawal effects may occur and thus, the dose of desvenlafaxine should be titrated down prior to discontinuation.
n3:volumeOfDistribution
3.4 L/kg, distribution into nonvascular compartments
n26:hasAHFSCode
n27:28-16-04-16
n3:foodInteraction
Take without regard to meals.
n3:mixture
n28:271B4F3D-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
~ 30%, protein binding is independent of drug concentration.
n3:salt
n3:synthesisReference
Karel Pospisilik, Lambertus Thijs, "Process for making desvenlafaxine." U.S. Patent US20070299283, issued December 27, 2007.
foaf:page
n14:rx-mono.aspx?contentFileName=pri2009.html&contentName=Pristiq&contentId=611 n22:pristiq-drug.htm n23:desvenlafaxine-succinate.html
n3:IUPAC-Name
n5:271B4F48-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4F4E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4F4D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4F4A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4F4B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4F4C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4F5E-363D-11E5-9242-09173F13E4C5 n5:271B4F46-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4F5F-363D-11E5-9242-09173F13E4C5 n5:271B4F44-363D-11E5-9242-09173F13E4C5 n5:271B4F47-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4F45-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n29:N06AX23
n3:H-Bond-Acceptor-Count
n5:271B4F54-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4F55-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4F4F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4F50-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4F52-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4F51-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4F53-363D-11E5-9242-09173F13E4C5
n3:absorption
Absolute bioavailability is approximately 80% and is unaffected by food. Peak plasma concentration is reached in 7.5 hours.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
93413-62-8
n3:category
n3:containedIn
n4:271B4F3E-363D-11E5-9242-09173F13E4C5 n4:271B4F3F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4F5A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4F5C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4F5D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4F59-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4F58-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4F5B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4F49-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4F56-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4F57-363D-11E5-9242-09173F13E4C5